MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, ...

CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) “This collaboration underscores our commitment to ...

MADISON, Wis., November 11, 2025--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate ® MSI Dx Analysis System as a companion diagnostic designed to identify ...

First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...

MADISON, Wis., February 03, 2026--(BUSINESS WIRE)--The National Medical Products Administration (NMPA) has approved the OncoMate ® Microsatellite Instability (MSI) Detection Kit as a Class III in ...

CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation ...

Promega Corporation announced today its intent to develop the Promega OncoMate microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte's anti-PD-1 drug candidate ...

The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended ...

CDx IVD kit will be used to identify patients with the MSI biomarker who may be eligible for potential treatment with Jemperli (dostarlimab-gxly) Promega Corporation today announced it plans to ...